Proyectos destacados

1. Red transpirenaica de terapias avanzadas en linfoma no Hodgkin (THERAVLINFO). Funding agency: POCTEFA-INTERREG. EFA123/1. Duration 2024-2026. Role: PI and coordinator.

Código: EFA 123/1.

Duración: 01/01/2024
Vascularized lymphoma on-chip: a multifaceted tool for translational research (MyLymphoTool). Caixa Research Health 2022, HR22-00395. Duration 2022-2025

Duración: 01/12/2022
3. Dual CD19-CAR-T approaches to counteract antigen escape and tumor microenvironment immune suppression in FL. Follicular Lymphoma Foundation. Duration 2022-2024. Role: PI

Duración: 01/12/2022
4. Vascular and extracellular matrix remodeling in follicular lymphoma: implications in the transformation to an aggressive lymphoma and immunotherapy efficacy (VASCEM_LYMPHO). MINECO. PID2021-124894OB-I00. Duration 2022-2025. Role: PI

Duración: 05/10/2022
5. Patient Derived Organoids 2.0: Annotated immunocompetent organoid platforms in solid and hematological tumors as living labs for the optimization and design of current and novel immunotherapies and cellular therapies. CIBERONC (Strategic Action-Towards

Duración: 01/07/2021
Characterization of duvelisib activity in follicular lymphoma and macrophages crosstalk

Investigador/a principal: Patricia Pérez Galán.
Financiador: Janssen Pharmaceuticals .

Duración: 01/01/2020 - 31/12/2020
Multi-cellular interactions in the progression of chronic inflammatory diseases and lymphoproliferative disorders: 3D models to investigate targeted immune therapies -3DIMMUNETARGET

Investigador/a principal: Maria Cinta Cid Xutgla, Patricia Pérez Galán.
Financiador: Ministerio de Economia y Competitividad (MINECO) .

Código: SAF 2017- 88275-R.

Duración: 01/01/2018 - 31/12/2020
Cross-border network of personalized immunotherapies in Non-Hodgkin Lymphoma -IMLINFO (POCTEFA-INTERREG).

Investigador/a principal: Patricia Pérez Galán.
Financiador: INTERREG V-POCTEFA .

Código: EFA281/16.

Duración: 01/01/2018 - 31/12/2021
Crosstalk between lymphocytes and their microenvironment in chronic inflammatory diseases and lymphoproliferative disorders as a target for new therapeutic intervention

Investigador/a principal: Patricia Pérez Galán.
Financiador: Institut d`Investigacions Biomèdiques August Pi i Sunyer (Sede o evento); Ministerio de Economia y Competitividad (MINECO) ; PROYECTOS I+D+I RETOS INVESTIGACIÓN (Programa financiador competitivo).

Código: SAF2014-57708-R.

Duración: 01/10/2015 - 30/09/2018
Crosstalk between lymphocytes and their microenvironment in chronic inflammatory diseases and lymphoproliferative disorders as a target for new therapeutic intervention

Investigador/a principal: Patricia Pérez Galán.
Financiador: Ministerio de Economía y Competitividad .

Código: SAF 2014/57708R.

Duración: 01/01/2015 - 01/01/2017

La investigación de este grupo se puede llevar a cabo gracias a los financiadores.

Proyectos destacados

1. Red transpirenaica de terapias avanzadas en linfoma no Hodgkin (THERAVLINFO). Funding agency: POCTEFA-INTERREG. EFA123/1. Duration 2024-2026. Role: PI and coordinator.

Vascularized lymphoma on-chip: a multifaceted tool for translational research (MyLymphoTool). Caixa Research Health 2022, HR22-00395. Duration 2022-2025

3. Dual CD19-CAR-T approaches to counteract antigen escape and tumor microenvironment immune suppression in FL. Follicular Lymphoma Foundation. Duration 2022-2024. Role: PI

4. Vascular and extracellular matrix remodeling in follicular lymphoma: implications in the transformation to an aggressive lymphoma and immunotherapy efficacy (VASCEM_LYMPHO). MINECO. PID2021-124894OB-I00. Duration 2022-2025. Role: PI

5. Patient Derived Organoids 2.0: Annotated immunocompetent organoid platforms in solid and hematological tumors as living labs for the optimization and design of current and novel immunotherapies and cellular therapies. CIBERONC (Strategic Action-Towards

Characterization of duvelisib activity in follicular lymphoma and macrophages crosstalk

Multi-cellular interactions in the progression of chronic inflammatory diseases and lymphoproliferative disorders: 3D models to investigate targeted immune therapies -3DIMMUNETARGET

Cross-border network of personalized immunotherapies in Non-Hodgkin Lymphoma -IMLINFO (POCTEFA-INTERREG).

Crosstalk between lymphocytes and their microenvironment in chronic inflammatory diseases and lymphoproliferative disorders as a target for new therapeutic intervention

Crosstalk between lymphocytes and their microenvironment in chronic inflammatory diseases and lymphoproliferative disorders as a target for new therapeutic intervention

Principales financiadores